Mereo Biopharma Ownership

MREO
 Stock
  

USD 0.86  0.04  4.88%   

Some institutional investors establish a significant position in stocks such as Mereo Biopharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Mereo Biopharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Additionally, see Correlation Analysis.
  
Mereo Biopharma Group holds a total of 108.9 Million outstanding shares. The majority of Mereo Biopharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mereo Biopharma Group to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mereo Biopharma Group. Please pay attention to any change in the institutional holdings of Mereo Biopharma as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Mereo Stock Ownership Analysis

About 80.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mereo Biopharma Group recorded a loss per share of 3.34. The entity had not issued any dividends in recent years. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. To find out more about Mereo Biopharma Group contact Denise ScotsKnight at 44 33 3023 7300 or learn more at https://www.mereobiopharma.com.

Mereo Biopharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Mereo Biopharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Mereo Biopharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Mereo Biopharma Group specific information freely available to individual and institutional investors to make a timely investment decision.
12th of September 2022
Other Events
View
23rd of August 2022
Unclassified Corporate Event
View

Mereo Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Mereo Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mereo Biopharma Group backward and forwards among themselves. Mereo Biopharma's institutional investor refers to the entity that pools money to purchase Mereo Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Rubric Capital Management LpCommon Shares16.8 M18.8 M
Point72 Asset Management LpCommon Shares10 M11.2 M
Orbimed Advisors LlcCommon Shares9.7 M10.9 M
Suvretta Capital Management LlcCommon Shares9.1 M10.2 M
Rock Springs Capital Management LpCommon Shares6.2 MM
Clearline Capital LpCommon Shares3.1 M3.4 M
Citadel Advisors LlcCommon Shares2.8 M3.1 M
Note, although Mereo Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Mereo Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Probability Of Bankruptcy Now

   

Probability Of Bankruptcy

Get analysis of equity chance of financial distress in the next 2 years
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Mereo Biopharma Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Correlation Analysis. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.